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A randomised trial of octreotide vs best supportive care only in advanced
gastrointestinal cancer patients refractory to chemotherapy
S Cascinu, E Del Ferro and G Catalano
Servizio di Oncologia, Ospedali Riwiti, P. ke Cinelli 4, 6110() Pesaro, Italy.
Sry Octreotde, a somastain analoue, has been shown to inhibit the growth of strointestinal
cancrs n vro and in vio. To assess the ant-tumour effect of octreoide, we performda randomised trial
comparing octreotide with best suporive care in advanced astrointestinal cancer patients refractory to
chmother . A total of 107 patients with advanced gstrointestinal cancer refratory to c o r w
randomid to recev octreotde at the doew of 200pg three times a day for 5 days a week, or the best
supportie care only. The primary outcome variable was the survival duration. Respone rate was an outcome
variable of secondary ion c Fifty-five patets (15 16 pancreas, 24 colon-rectum) romved
octreotde, whie 52(14 stomach, 16 paneas, 22 colon-rectum) reeived the best suPportive cam. Patients
teated with octreoide had a nt adta in durami of survival with a median survival time of 20
weeks vs 11 in the control group (P<0.0001). This advantage was present also considaing the survival data
for each tumour group. Twenty-five patients (45%) given octreotile showed stablc disea vs onlyeight (15%)
in the control group (P<O.001). In conlusion, ocureotide thrapy sem to confer a survival bencfit in
advaned gastromtestinal cancr patiets refractory to cmothapy. Additional studies will be needed to
confirm these rsults and to clarify other question about dose and schedule of octreotde.
Klyqw. advanc gastrointestinal cs; octreotide
Gastrointestinal tumours are one ofthe commonest causes of
cancer deaths in Westen countries. Few patients present an
early state of disease and the treatment of advanced gast-
rointestinal tumours is far from satisfactory. The contribu-
tion of cytotoxic chemotherapy has been modest and limited
to palliation (Ahlgren and MacDonald, 1992). Therefore, ifa
non-toxic and safe drug is found that can slow the growth of
tumour, it could represent an advantage in the managemet
of diseases which are difficult to treat effectively. One of the
areas under investigation is the role of gastrointestinal hor-
mones in the growth of tumours arising from the gastrointes-
tinal tract. In fact, peptide hormones, such as gastrin and
cholecystokinin have been shown to promote the growth and
differentiation ofnormal as well as malignant gastrointestinal
cells in vitro and in vivo (Kobory et al., 1982; Hudd et al.,
1989; Townsend et al., 1989). The mehanism ofaction is not
well known but is probably mediated by speific hormone
receptors present in normal and tumour cells; thus there have
been efforts to develop receptor antagonists as anti-cancer
agents (Chang et al., 1986; Singh et al., 1986).
One of the most important naturally occurring antipro-
liferative hormones is somatostatin. It has been shown to
inhibit cellular proliferation in normal and neoplastic mucosa
of stomach, pancreas and colon-rectum (Reichin, 1983).
However, the short half-life of native somatostatin and the
need for its intravenous administration makes long-term
somatostatin therapy impactical (Sheppard et al., 1979).
Octreotide, a synthetic somatostatin analogue, differs from
natural somatostatin, which has a half-life of 1-3 in
that it has higher potency and a much longer half-life (Bauer
et al., 1982).
While it is now considered an accepted treatment for
neuroendocrine tumours of the gut, such as carcinoids,
insulinomas and VIPomas, it is still unclear whther oct-
reotide is effective against non-endocrine gastrointinal
tumours (Kraenzlin et al., 1985; Boden et al., 1986; Kvols et
al., 1987; Saltz et al., 1993).
In fact, although experimental evidence for antipro-
liferative activity has been shown for octreotide in gastric,
pancreatic and colorectal cancers, initial clinical trials gave
confliing results (Savage et al., 1987; Klijn et al., 1990).
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In order to assess the anti-tumour effects of octreotide, we
performed a randomised trial comparing octreotide with best
supportive care in patients with advanced gastrointestinal
cancer refractory to chemotherapy.
P ri ad &hor
Advanced gastrointestinal cancer patients refractory to
chemotherapy wem eligible for this study. Other admission
criteria icluded: age <75 years; an ECOG performance
status of 0-2; measurable disease; absence of concomitant
diseas; adequate hepatic (serum enzyme values not higher
than twice normal levels: total bilirubin <2.0 mgdl-1';
alkaline phosphatase <516 U 1I1; aspartate aminotransferase
(AST) <62 U1I1; lactate dehydrogenase <920 U1-1); renal
(serum creatinine level <1.5 mg dl1; blood urea nitrogen
(BUN) <55 mgdl1); and bone marrow (WBC >4000p1 1;
platelet count >100000il'; Hb >lOOgl-' functions.
Pretreatment evahlation inluded a physical examintion,
complete blood count, biochemical scrning profile, chest
radiograph and a computerised tomographic (CT) scan of
pertinent indicator lesions.
All patients were informed of the investigational nature of
this trial, and all patints consented to participation before
randomisation to octreotide or control group.
Advanced gastrointestinal cancer patients with progressive
diseae after first-lne chemotherapy were stratified according
to performance status (ECOG scale) and primary tumour,
and then they were randomised to receive octreotide or best
supportive care only. No crossover to octreotide treatment
was allowed for patients randomised in the control group.
Octreotide therapy was given by subcutaneous injection at
the dose of 200 ag three times daily for 5 days a week.
Treatment was continued until there was disease progres-
sion, unacceptable toxicity or patient refusal. Patients in both
arms could receive supportive care such as haemotrans-
fusions for anaemic state; antibiotics to control infections;
analgescs, including non-steroidal anti-inflammatory drugs
and opioids; corticosteroids; and vitamin suppklments.
Furthemore, patients could be treated with radiation
therapy for painful osseous metastases and pelvic recur-
rences. In the cae ofjaundie due to an obstruction of the
biliary tree a peutaneous transhepatic bliary drainage
could be placed.SCasn eta
Every 2 weeks, patients of both arms were looked after in
the same setting and by the same physicn and nursing staff
in order to record both side-effects of treatment with oct-
reotide and possible complications related to the neoplastic
disease.
Tumour measurements were obtained at entry into the
study and every 8 weeks. Responses were evaluated using the
criteria of Miller et al. (1981). Patients in both arms were
followed until death.
The study was designed as a randomised tial in which at
least 50 patients were to be assigned to each of the two
treatment arms. The sample size was determined in order to
detect a 30% difference in absolute increase in survival
between the two treatment groups, with alpha and beta error
of 0.05 and 0.1 respectively. A benefit in survival of at least
30% was thought to have a positive clnical impact consider-
ing both the poor survival time of advanced gastrointestinal
cancer patients refractory to chemotherapy and the aspects
related to the economic cost and compliance ofthe octreotide
treatment.
Randomisation using cards from a computer-generated list
in sealed envelopes was performed by a person not involved
with the care or evaluation of the patients. The primary
outcome variable in this study was the survival length. Out-
come variable of secondary importance was response rate.
Survival was calulated from the date ofrandomisation using
the Kaplan-Meier estimates. The log-rank test was used to
assess the difference between survival curves.
The chi-square test was used to analyse the statistical
Evaluable patients
Sex
Male
Female
Age
Median
Range
Performance statusa
0
I
H
Primary tumor
Stomach
Panecreas
Colon-rectum
Sites of metastases
Liver
Lung
Peritoneum
Lymph node
Bone
significce of the difference in clinical responses (Glantz,
1992).
Resut
Patients
Between January 1990 and December 1992, 107 patients with
advanced gastrointestinal carcinoma were included in the
study. Patient characteristics are summarised in Table I.
Fifty-five patients received octreotide and 52 the best suppor-
tive care only. In the octreotide arm primary tumours were:
stomach 15, pancreas 16, colon-rectum 24; in the control
group, stomach 14, pancreas 16, colon-rectum 22.
Previously chemotherapeutic regimens were: for gastric
cancer a weekly adminisation of 5-fluorouracil (5-FU), 6S-
leucovorin, cisplatin and epidoxorubicin; for pancreatic
cancer a weekly administration of 5FU, leucovorin and
interferon alpha-2b 3 MU three times a week; for colorectal
cancer a 5 day schedule of 5FU, leucovorin and interferon
alpha-2b, with cycles repeated every 3 weeks.
Median time to progression from onset of chemotherapy
was 6 months in the octreotide arm and 5 months in the
control group (Table I). In the octreotide arm 12 patients
responded to previous chemotherapy vs 13 in the control
group. Both arms were well balanced also for other possible
prognostic factors, such as performance status, liver function
tests and sites of metastases.
Table I Paient characteristics
Octreotide
55
35
20
68
39-71
3
30
22
15
16
24
28
10
19
8
3
Response to chemotherapy
Complee response
Partial response
Stable disea
uprgesve disease
Median time to progression from
chemotherapy onset (months)
Stomach
Pancreas
Colon-rectum
Biochemical tests (median)
LDH (230-460UI-1)
Alkaline phosphatase (91-258)
AST (2-31 U 1-)
Albumin (3-4.5gdl-')
'ECOG performance status.
11
12
31
6 (2-9)
5
2
6
480
(260-805)
235
(172-470)
54
(45-61)
3.1
(2.7-4.1)
Controls
52
30
22
66
44-72
4
30
18
14
16
22
23
11
16
9
1
0
13
20
19
5 (2-10)
5
2
6
470
(270-920)
270
(135-510)
58
(38-62)
3.0
(2.5-3.6)Od_hi W _ mms
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Octreotide therapy
The mean duration of octreotide therapy was 12 weeks
(range 6-32 weeks). Four gastric cancer patients received
octreotide for only 6 weeks because of a severe impairment
of general conditions owing to rapid dise progreson.
They died after only 2 weeks. For the same reason a panc-
reatic cancer patient received octreotide for only 7 weeks.
This thrice-daily dosing adm i subcutaneously was
generally well tolerated. Only five patients suffered from pain
at injection sites, but it did not determine the refusal of
treatment or reduce their compliance in taling the drug.
Supportive care
Ten patients in the octreotide arm and nine in the placebo
arm required haemotransfusions. In two patients in the
placebo arm a percutaneous transhepatic biliary drain was
place to reduce hyperbilrubinaemia. No patient in either arm
developed infections requiring hospitalisation. Antibiotic
treatment was given in two patients in the octreotide arm (for
pneumonia and urinary infection) and in two patients in the
control group (pneumonia). Corticosteroids (methylpred-
nisolone 8-24mg day-') were administered orally as
adjuvant analgesic drugs in three patients with tumour
infiltration of lumbosacral plexus, and to produce increased
appetite and weight gain in another three patients in the
octreotide arm, while in the plaebo group prednisone, at the
dose of 25 mg day-', was given to four patients with
weakness and anorexia to obtain a sense of well-being.
Radiotherapy was used in four patients in the octreotide arm
(two bone metastases and two symptomatic pelvic recur-
rence) and in six patients in the control group (one bone
metastasis and five pelvic recurre).
Response
No patient achieved an objective response. Twenty-five of 55
patients (45%) given octreotide (seven stomach, seven panc-
reas, 11 colon-rectum) showed stable disease vs only 8 of 52
(15%) in the control group (three somach, two pancreas,
three colon-rectum) (P<0.001).
Patients treated with octreotide had a signnt advantage
in survival duration with a median survival time of 20 weeks
vs 11 weeks in the control group. This advantage in survival
was present analysing either all the patients or consiering
each primary tumour separately (Figures 1-4).
Twenty-two patients (40%) treated with octreotide showed
relief of pain, with concomitant discontinuation in analgesc
treatment requirements.
r-
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Toxicity
No severe toxicity was recorded in the octreotide arm requir-
ing the discontinuation of octreotide. Twenty patients had
asymptomatic hyperglycaemia and ten mild steatorrhoea.
Tlhree patients had abdominal cramps which disappeared
spontaneously after a few days of continued therapy.
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Flge 2 Survival curves comparing patients with stomach
cancer treated with octreotide (n = 15) or not (n = 14). Tbere is
staiical difference between the two auves Mantel-Cox (log-
rank), P= 0.003.
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Fuwe 3 Survival curves comparing patients with pancreatic
cancer trated with octrootide (U, n= 16) or not (0, n= 16).
There is statistkcl differnce between the two curves:
Mantel-Cox (log-rank), P=0.001.
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Fgwe 1 Survival curve of patients treated with octreotide (U,
n= 55) vs controls (0, n = 52). The diferce in surnvival was
sgnificant by the Mantel-Cox (og-ank) test, P<0.001.
Figwe 4 Survival curves comparing patients with colorectal
cancer aed with octeotide (U, n=24) or not (0, n=22).
There is stcal differene between the two arm: Mantel-Cox
(Iog-rank), P= 0.001.OC&oo&kin - csu
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Somatostatin plays an important modulatory role in the
secretion and growth-promoting functions of several gast-
rointesftinal hormones that have been shown to stimulate the
growth of tumour arising in the gastrointestinal tract (Town-
send et al., 1987).
The exact mechanism of action of somatostatin is not
clear. It may influence tumour growth directly at the intracel-
lular level, by interactions with membrane receptors, or
indirectly through suppression of hormones or tumour
growth factors (Reichlin, 1983).
Somatostatin receptors have been shown to be present on
normal and tumoral gastrointestinal mucosa. Gastric, pan-
creatic and colorectal cancers have been demonstrated to
possess high-affinity somatostatin receptors (Reyl & Lewin,
1982; Reyl-Desmars and Lewin, 1982; Dy et al., 1992).
There are, however, other mechanisms that are likely to be
involved, such as inhibition of the secretion of growth hor-
mone and insulin, and direct inhibition of insuln-lke growth
factor (IGF-1), IGF-ll and other growth factors that have
been recntly shown to be potent stimulators of gastrointes-
tinal tumour cell prolferation (Durrant et al., 1991; Waston
et al., 1992).
Other studies have suggested that somatostatin can sup-
press the release or action of the gastrointestinal hormones
gastrin, choleystolkinin (CCK) and secretin. This is a partic-
ularly attractive hypothesis, because gastrin and CCK are
important trophic hormones for gastrointestinal mucosal
cells. This could partly explain the anti-cancer effect of
somatostatin (Harty et al., 1985; Schally et al., 1986; Chan-
ley et al., 1989; Kamik et al., 1989; Watson et al., 1989).
Another possibe mechanim by which somatostatin might
inhibit tumour growth is interference with the synthesis of
autocrine growth factors by tumour cells. This action of
somatostatin might involve the inhibition of not only endo-
crine but also paracrie and autocrine growth factors (Gous-
tin et al., 1986; Lippman et al., 1986). Somatostatin could
also inhibit oncogene products, several of which are similar
to growth factors or their receptors (Doolittle et al., 1983;
Downward et al., 1984). Consequently, somatostatin could be
of value for impding the growth of cners, such as gastric,
pancreatic and colorectal, in which gastrointestinal hormones
as well as growth factors might be involved (Schally et al.,
1987). However, the half-life of somatostatin in plasma
(estimated to be 1.1-3.0 min in humans) presents difficulties
for its clinical use (Sheppard et al., 1979). For this reason,
several somatostatin analogues have been developed. Oct-
reotide has a longer half-life (90Omm) and a duration of
action of about 8 h after subcutaneous injection (Bauer et al.,
1982). It is three times more potent in vitro and up to 70
times more active in vivo than native somatostatin.
Several studies have demonstrated that octreotide is able to
inhibit in vitro or in vivo growth of gastrointestinal tumours
(Reyl and Lewin, 1982; Townsend et al., 1987; Schally, 1988).
On the basis of experimental data, pilot clinical trias with
octreotide were crried out in gastrointesinal tumours. How-
ever, in spite of the intriguing preclinical data, initial
preliminary studies led to disappointing results.
Klijn et al. (1990) treated 34 patients with gastrointestinal
amncers, obtaining 27% sble diseas, but surival remained
discouraging. However, it was of interest that most patients
experienced subjective improvement in the absence of serious
side-effects. Savage et al. (1987) treated ten patients (four
pancreatic cancers, four colorectal cancers, two gastric
cancers) without finding any indication that ocbeotide can
alter the rate ofgrowth of advanced gastrointestinal tumours.
A recent trial evahlating octreotide (150pg thrice daily,
subcutaneously) vs plaebo in 260 advanced chemonaive col-
orectal cancer patients had showing no difference in terms of
time to progression and survival betl n the two arms sug-
gested that octreotide, at least in this dose and ul, is
ineffective in advanced colorectal canr (Krook atat., 1993).
However, inthis study, published until now only mthe form
of a meeting abstract, some important aspects of outcome,
such as the duration of octreotide therapy, the further treat-
ment received by patients with progressive disease after oct-
reotide and the supportive care pracised in patients becom-
ing symptomatic during the course of disease, are not
available, thus limitng, in our opinion, a complete interp-
retation of these data.
The only ptially positve study was presented by Smith et
al. (1992), who found a modest increase in survival in 12
colorectal canr patients treated with octreotide, but no
objecive responses.
These conflicting results probably rflect the difficulty in
assssing the activity of an agent such as ocuotide and the
lack ofknowledge ofits proper dose and scheme of administ-
ration. In fact, apart from the study of Krook et al. (1993),
previous pilot stude were performed to evaluate the clinicl
activity of octreotide in terms of objective responses (Savage
etal., 1987; Klijn etal., 1990; Smith etal., 1992). However, it
is possible that tratment with octreotide or other similar
agents could be valuable if it consistetly results in stabilisa-
tion ofdisease, and if this is associated with an improvement
in survival.
A second problem arisng from the studies cited above is
the octreotide dose, which was probably too low to achieve
an anti-tumour effect. In fact, experimental data suggest that
a serum octreotide level of about 1200ngml[', which is
equivalent to 1.2 x 10'6M, appears to be effective (Dyet al.,
1992). This concentration can be achieved clinicly after a
subcutaneous injection of at least 200pg of octreotide
repeated every 8 h. (Del Pozo etal., 1988). On the contrary,
octreotide was generally adminired at a dose of 200pg
twice daily or 100-150pg thrice daily, this corresponds to
60-75% of the optimal dose as judged from pharma-
cokinetic models (Del Pozo et al., 1986; Dy et al., 1992).
Another critical point in previous studies could be the
administration of octreotide for a long time without discon-
tinuation. Preclinical data have revealed that after continuous
administration of octreotide desensitisation or tachyphylaxis
of its inhibitory effect on receptors and plasma growth hor-
mone, insulin and IGF-I concentrations develops within
6-10days, but this could be reduced if 'drug-free' days were
inserted in the protocol (Redding and Schally, 1983;
Lamberts et al., 1987).
These experimental data suggest that the discouraging
results obtained until now could be caused by the use of a
suboptimal schedule.
Our study, employing subcutaneous octreotide 200pg
three times a day for 5 days a week, does suggest an advan-
tage for octreotide therapy in gastrointestinal cancer patients.
We observed a doubling of survival time in treated patients
with respect to the control group, considering either all the
patients or each primarytumour separately. Nevertheless, we
are conscious that the interpretation of our results requires
caution, particularly in view of the negative randomised
NCCGT trial in untreated colorectal cancer patients (Krook
etal., 1993). Although in our study both groups of patients
were looked after by the same medical and nursing staf,and
factors predicting for outcome, such as performance status,
sites of metastases, response to previous chemotherapy and
adequate orgn functions were well balanced in the two
arms, the possble confounding effects of different teminal
care practic in the two arms and the lack of a double-blind
deign cannot exclude competely a degree of bias in the
conduct of the study. It is of note that, as in other studies,
40% of patients in the octreotide arm showed subjective
improvement with relief of pain and discontinuation of
analgesc terapy. This sugest that quality of life could be
improved by octreotide therapy. Unfortunately, we had not
included a quality of life assessment in this trial. Fuirthe
studies, especially in a population such as this, should con-
sider some sort of quality of life measurements.
In conclusion, although our results are encouragng, we
thinkr that additional studies need to confirm these favourable
data and to clarify other important questions, e.g. the rela-
tionship between somatostatin receptors status and response,
the optimal dose and timing of octreotide administration
and, last but not kast, the impact of octroide treatment in
terms of not only survival but also patients' quality of life.0rd mpkoinisd _
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